Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: A new therapeutic approach to treatment of hypercholesterolemia

Cardiology in Review

Volumn 17, Issue 2, 2009, Pages 70-76

  Seiki, Stephanie ^a   Frishman, William H ^b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cholesterol synthesis inhibition; Downstream enzymatic inhibition of cholesterol synthesis lapaquistat; Oxidosqualene cyclase inhibition; Squalene monooxygenase inhibition; Squalene synthase inhibition

Indexed keywords

3 [(3,3' BITHIOPHEN 5 YL)METHOXY] N (6,6 DIMETHYL 2 HEPTEN 4 YNYL) N ETHYLBENZYLAMINE; 3BETA (2 DIETHYLAMINOETHOXY)ANDROST 5 EN 17 ONE; ATORVASTATIN; BMS 187745; BMS 188494; ENZYME INHIBITOR; EP 2302; EP 2306; ER 27856; ER 28448; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANOSTEROL SYNTHASE; LAPAQUISTAT; MEVINOLIN; OXIDOSQUALENE CYCLASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; RPR 107393; SIMVASTATIN; SQUALENE MONOOXYGENASE; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; SQUALESTATIN; TAK 475; TELLURIUM; UNCLASSIFIED DRUG; YM 53601; ZARAGOZIC ACID;

ACIDOSIS; ANTIINFLAMMATORY ACTIVITY; BACKACHE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MYOPATHY; NONHUMAN; REVIEW;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; OXAZEPINES; PIPERIDINES; SQUALENE;

EID: 67649961784     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181885905     Document Type: Review

References (45)

1. Castelli W, Garrison R, Wilson P. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256: 2835-2838.
2. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248:1465-1477.
3. Stamler J, Dariglus ML, Garside DB. Relationship of baseline serum cholesterol levels in 3 large cohorts of young men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000;284:311-318.
4. Gould A, Davies G, Alemao E. Cholesterol reduction yields clinical benefit: meta-analysis including recent trials. Clin Ther. 2007;29:778 -794.
5. Hachinski V, Gaffagnino C, Beaudry M. Lipids and strokes: a paradox resolved. Arch Neurol. 1996;53:303-308.
6. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults. JAMA. 2001;285:2486-2497.
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. JAMA. 1996; 3:213-219.
8. Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther. 2007;29:763-777.
9. Grünler J, Ericsson J, Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta. 1994;1212:259-277.
10. Okazaki H, Tazoe F, Okazaki S, et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. J Lipid Res. 2006;47:1950-1958.
11. Do R, Kiss RS, Gaudet D, et al. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin Genet. 2009;75:19-29.
12. Charlton-Menys V, Durrington P. Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs. 2007;67:11-16.
13. Frishman WH, Retter A, Misailidis J. Innovative pharmacologic approaches to the treatment of myocardial ischemia. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill; 2003:655-690.
14. Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res. 2002;43:2-12.
15. Hiyoshi H, Yanagimachi M, Ito M, et al. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur J Pharmacol. 2001;431:345-352.
16. Hiyoshi H, Yanagimachi M, Ito M, et al. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J Lipid Res. 2003;44:128-135.
17. Burnett J. Drug evaluation: TAK-475-an oral inhibitor of squalene synthase for hyperlipidemia. Curr Opin Investig Drugs. 2006;7:850-856.
18. Tavridou A, Kaklamanis L, Megaritis G, et al. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur J Pharmacol. 2006;535:34-42.
19. Wagner M, Toews AD, Morell P. Tellurite specifically affects squalene epoxidase: investigations examining the mechanism of tellurium-induced neuropathy. J Neurochem. 1995;64:2169-2176.
20. Hiyoshi H, Yanagimachi M, Ito M, et al. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. J Lipid Res. 2000;41:1136-1144.
21. Amin D, Rutledge R, Needle S, et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther. 1997;281:746-752.
22. Bostedor R, Karkas J, Arison B, et al. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J Biol Chem. 1997;272:9197-9203.
23. Nishimoto T, Amano Y, Tozawa R, et al. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol. 2003;139:911-918.
24. Amano Y, Nishimoto T, Tozawa R, et al. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol. 2003;466:155-161.
25. Sharma A, Slugg P, Hammett J, et al. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol. 1998;38:1116-1121.
26. Piper E, Price G, Chen Y. TAK-475, a squalene synthase inhibitor provides lipid profile in hyperlipidemic subjects [abstract]. Circulation. 2006;114(18 Suppl): II-288.
27. Perez A, Kupfer S, Chen Y. Addition of TAK-475 to atorvastatin provides incremental lipid benefits [abstract]. Circulation. 2006;114 (18 Suppl):II-113.
28. Nishimoto T, Tozawa R, Amano Y, et al. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol. 2003;66:2133-2139.
29. Nishimoto T, Ishikawa E, Anayama H. Protective effects of squalene synthetase inhibitor, Lapaquistat acetate (TAK-475) on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007;223:39-45.
30. Raiteri M, Arnaboldi L, McGeady P, et al. Pharmacologic control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharm Exp Ther. 1997;281:1144-1153.
31. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231-2237.
32. Goldstein J, Brown M. Regulation of the mevolonate pathway. Nature. 1990;343:425-430.
33. Chugh A, Ray A, Gupta J. Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003;42:37-50.
34. Hidaka Y, Hotta H, Nagata Y, et al. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells. J Biol Chem. 1991;266:13171-13177.
35. Horie M, Sawasaki Y, Fukuzumi H, et al. Hypolipidemic effects of NB-598 in dogs. Atherosclerosis. 1991;88:183-192.
36. Wentzinger L, Bach T, Hartmann M. Inhibition of squalene synthase and squalene epoxidase in tobacco cells triggers an up-regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase. Plant Physiol. 2002;130:334-346.
37. Matzno S, Yamauchi T, Gohda M, et al. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J Lipid Res. 1997;38:1639-1648.
38. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol. 2000;131:63-70.
39. Eisele B, Budzinski R, Müller P, et al. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997;38:564-575.
40. Dollis D, Schuber F. Effects of a 2,3-oxidosqualene-lanosterol cyclase inhibitor 2,3:22,23-dioxidosqualene and 24,25-epoxycholesterol on the regulation of cholesterol biosynthesis in human hepatoma cell line HepG2. Biochem Pharmacol. 1994; 48:49-57.
41. Mark M, Muller P, Maier R, et al. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996;37:148-158.
42. Peffley D, Gayen A. Inhibition of squalene synthetase but not squalene cycles prevents mevalonate-medicated suppression of 3-hydroxy-3-methyglutaryl coenzyme A reductase synthesis at a posttranscriptional level. Arch Biochem Biophys. 1997;337:251-260.
43. Morand O, Aebi J, Dehmlow H, et al. Ro 48-8. 071, a new 2,3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997;38: 373-390.
44. Peffley D, Gayen A, Morand O. Down-regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase mRNA levels and synthesis in syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4'-(6-allyl-ethyl-amino- hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-me thanone (Ro 48-8071): comparison to simvastatin. Biochem Pharmacol. 1998;56:439-449.
45. Cenedella R, Jacob R, Borchman D, et al. Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor. J Lipid Res. 2004;45:1232-1241.